• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21045 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2017     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the LEADER study on liraglutide - rapid report]
2006     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of the effectiveness of the intraoperative detection of the sentry ganglion in solid tumours]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [Assessment of the effectiveness of sublingual immunotherapy and subcutaneous immunotherapy in allergic rhinitis and asthma]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the benefit of screening in persons under 55 years of age with a family history of colorectal cancer]
2018     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of the application of fluoride varnish on milk teeth to prevent the development and progression of initial caries or new carious lesions - rapid report]
2002     Finnish Office for Health Care Technology Assessment (Finohta) [Assessment of telemedicine in the Northern Ostrobothnia hospital district]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery for the treatment of patients with brain metastases]
2021     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment of stereotactic radiosurgery (SRS) for the treatment of vestibular schwannoma requiring intervention]
2014     Haute Autorite de sante (HAS) [Assessment of spinal cord stimulation]
2014     Haute Autorite de sante (HAS) [Assessment of real-time optical endomicroscopy performed during mapping of Barrett's esophagus (BE) (for diagnosis of BE-associated early neoplasia)]
2019     Haute Autorite de sante (HAS) [Assessment of pulp wound protection by direct pulp capping]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Assessment of Perinatal Outcome after Sustained Tocolysis for Early Labour (APOSTEL II)]
2014     Haute Autorite de sante (HAS) [Assessment of non-invasive methods for measuring liver fibrosis in chronic hepatitis B. Initial assessment and follow-up of non-treated adult patients]
2010     Haute Autorite de sante (HAS) [Assessment of medical devices for home infusion]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of healthcare status and therapeutic recommendations concerning attention deficit hyperactivity disorder]
2011     Haute Autorite de sante (HAS) [Assessment of glomerular filtration rate and serum creatinine levels in the diagnosis of chronic kidney disease in adults]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Assessment of factors related to the pharmaceutical expenditure in Primary Care, and prescription quality in chronic diseases]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Assessment of effectiveness and safety of Cyberknife and Gamma knife radiosurgery in intra and extracraneal lesions' treatment (update)]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Assessment of effectiveness and cost-effectiveness of HPV testing in primary screening for cervical cancer]
2009     Haute Autorite de sante (HAS) [Assessment of drug-eluting stents]
2015     Haute Autorite de sante (HAS) [Assessment of diagnostic and therapeutic parotid and submandibular sialendoscopy]
2015     Haute Autorite de sante (HAS) [Assessment of cardiovascular magnetic resonance compared to coronography and computed tomography]
2009     Haute Autorite de sante (HAS) [Assessment of breast implants, tissue expanders and external breast prostheses]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Assessment of bilateral cochlear implants in children. Indication criteria for cochlear implants in children and adults]
2012     Haute Autorite de sante (HAS) [Assessment of an epiretinal prosthesis and its implantation procedure]
1999     Finnish Office for Health Care Technology Assessment (Finohta) [Assessment of an electronic referral and teleconsultation system between secondary and primary health care]
2015     Haute Autorite de sante (HAS) [Assessment of an edge-to-edge mitral valve repair clip and its implantation]
2019     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Assessment and interventions in care and services for older adults - an evidence map]
2022     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Assessment and analysis of studies on rare diseases - Rapid report]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Aspirin prescription pattern among diabetic patients for prevention of cardiovascular disease]
2013     National Evidence-based Healthcare Collaborating Agency (NECA) [Asian study on the value for a QALY: Korean results]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa: assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa (hypophosphatasia) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asfotase alfa (hypophosphatasia) - Addendum to Commission A19-89]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Asciminib (chronic myeloid leukaemia) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022     Canary Health Service [Artificial pancreas with dual release of insulin and pramlintide for treatment of type 1 diabetes mellitus]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Artificial liver support systems]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Artificial disc replacement]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Arthroscopy with joint washout in the treatment of knee arthrosis]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Arthroscopy of the knee joint for gonarthrosis]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Arthroplasty register for Germany]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Arthroplasty register for Germany]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Arterial stiffness measurement for cardiovascular risk classification in high blood pressure patients]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Arrhythmia ablation by EnSite NavX electroanatomical mapping]
2016     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Aromatase inhibitors in female breast cancer]
2014     The Swedish Council on Health Technology Assessment (SBU) [Aromatase inhibitors for early-stage breast cancer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Argon plasma coagulation for gastrointestinal lesions]
2015     The Swedish Council on Health Technology Assessment (SBU) [Arginine and caries prevention]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy) - Addendum to Commission A21-135]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Aquapheresis – ultrafiltartion for congestive heart failure]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Systematic review of the admission criteria in acute decompensated heart failure]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Efficacy and safety of pharmacological treatment for bipolar disorder]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Development of appropriateness explicit criteria for carotid revascularization]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies : appropriate admission explicit criteria for heart failure (HF)]
2009     Andalusian Health Technology Assessment Area (AETSA) [Appropriateness criteria for vertebral arthrodesis]
2009     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of recombinant activated factor VII in nonhaemophilic patients]
2000     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of Factor VIII in the treatment of haemophilia. A Literature review and opinions of an expert panel on the correct use of different preparations of Factor VIII]
2005     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of Factor VIII for treatment of hemophilia - A consensus conference]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in primary and secondary care : ultrasonography in breast pathology]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in acute abdominal pain]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Approach to personality disorders in the mental health system of the Basque Country]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Appraisal of the variability and suitability of prescribing antimicrobials in primary health care in the Basque Country]
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2011     Andalusian Health Technology Assessment Area (AETSA) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Applicability of sentinel-lymph-node detection and biopsy in the treatment of vulval cancer]
2014     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2010     Committee for New Health Technology Assessment (CNHTA) [APC gene,mutation[sequencing]]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2019     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Addendum to Commission A19-09]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Aortic valve replacement with rapid deployment or sutureless valves]
2009     Committee for New Health Technology Assessment (CNHTA) [Antroduodenal manometry]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Antipsychotic polypharmacy in the treatment of schizophrenia]
2020     National Committee for Technology Incorporation (CONITEC) [Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Antigermix – disinfection of endocavitary ultrasonography probes]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2012     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2015     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-coated drug-eluting stents for treatment of coronary artery stenosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Antibodies to pgp9.5 in small fiber neuropathy]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Antibiotic therapy in hospital, oral versus intravenous treatment]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-saccharomyces cerevisiae antibody test]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Anti-immunoglobulin E (omalizumab) for the treatment of allergic asthma in adults]
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-Heparin/Platelet Factor 4 antibody assey]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Anti-GD2 immunotherapy in patients with high risk neuroblastoma]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Annual Report 2010. German version.]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]